Sirflox: Randomised phase III trial comparing first-line MFOLFOX6 +/- BEVACIZUMAB (BEV) versus MFOLFOX6 +/- BEV plus selective internal radiation therapy (SIRT) in patients with metastatic colorectal cancer (MCRC) - analysis by presence or absence of extra-hepatic metastases, BEV treatment and site of first progression

Abstract

Abstract is not available.